3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Stomach Neoplasms
4
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pleural Effusion, Malignant
1
Neoplasms
1
Neoplasm Metastasis
1
Lung Neoplasms
1
Gastrointestinal Neoplasms
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Interventions
Carboplatin
71
Etoposide
63
Topotecan
42
Cisplatin
38
pembrolizumab
30
atezolizumab
26
durvalumab
22
Paclitaxel
16
Nivolumab
14
PM 01183
13
rovalpituzumab tesirine
11
Pemetrexed
11
amrubicin
9
Ipilimumab
9
Injections
9
Irinotecan
8
AMG 757
8
trilaciclib
7
etoposide phosphate
6
EC regimen
6
Drug Therapy
6
Docetaxel
6
Bevacizumab
6
tremelimumab
5
MLN 8237
5
Gemcitabine
5
130-nm albumin-bound paclitaxel
5
olaparib
4
chiauranib
4
budigalimab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Small Cell Lung Carcinoma
×
rilotumumab
×
Clear all
NCT00791154
2024-08-23
SCLC
NantCell, Inc.
Phase 1/2
Terminated
213 enrolled
16 charts